PATENT CLAIM ANALYSIS

Application Number: 16149420
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["424", "093210"]

Abstract:
The present invention concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in  Homo sapiens  of the RdCVF2 gene (SEQ ID NO: 10), orthologs, derivatives and fragments thereof, (ii) a polynucleotide coding for said polypeptide, (iii) a vector comprising said polynucleotide, and (iv) a host cell genetically engineered expressing said polypeptide; the use of such a composition for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder in a subject; and a method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder.

Claim (Index 9):
The method according to  claim 8 , wherein the neurodegenerative disorder is a disease associated with the degeneration of neurons selected in the group consisting of degenerative disorders of the central nervous system, degenerative disorders of the photoreceptors, and degenerative disorders of the olfactory neurons.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 97.0
- Lexical Diversity: 1.82895
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['12602736', '12745920', '14962337', '13909764', '13348435']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7471774834831849
- 35 USC 102 Novelty (BERT): 0.5413229693042563
- Combined Prediction Score: 0.7265920320652921
- Mean Citation Score: 290.12198
- Max Citation Score: 377.54755
- Similarity Product: 229.95885087419745

Labels:
- Claim Label 101: 0
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test